Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003324353 | SCV004028616 | likely pathogenic | Fanconi-Bickel syndrome | 2023-07-25 | criteria provided, single submitter | clinical testing | Variant summary: SLC2A2 c.59G>A (p.Gly20Asp) results in a non-conservative amino acid change located in the Major facilitator superfamily domain (IPR020846) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251128 control chromosomes. To our knowledge, no occurrence of c.59G>A in individuals affected with Fanconi-Bickel syndrome has been reported. At least one publication reports experimental evidence evaluating an impact on protein function showing lack of expression of the protein resulting in decrease of glucose transport(Michau_2013). The following publication have been ascertained in the context of this evaluation (PMID: 23986439). No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |